Venus Remedies has launched a novel formulation “ACHNIL” brand of “Aceclofenac- injection” in India. “ACHNIL” injection is a single shot last day long formulation. This novel formulation based on NDDS (Novel Drug Delivery System) technology will fill in the gap of long standing demand for better pain management therapies especially for aged population. The product will not only reduce the number of pricks but will also drastically reduce the side effects associated with the use of NSAIDs.
Further, the company already has secured patents from India as well as from Europe for this research product which are valid up to 2025 and will further reinforce the markets position of the company in India and the major European countries such as Germany, UK, France, Spain, Sweden, Italy and Switzerland.
ACHNIL acts directly by giving instant relief from acute pain and it is effective for the next 24 hours against the conventional daily dose of three injections of diclofenac given every 8 hours. The development of ACHNIL commenced at VMRC and took more than several years in the successful completion of the Phase I, Phase II and Phase III clinical trials and regulatory approvals from DCGI for products.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1771.65 |
Dr. Reddys Lab | 1170.05 |
Cipla | 1524.00 |
Lupin | 2041.00 |
Zydus Lifesciences | 859.80 |
View more.. |